Suchergebnisse - "Marks, Peter W"

PubPharm (66)

11

Unwavering Regulatory Safeguards for COVID-19 Vaccines

enthalten in: JAMA | 2020

von Shah, A. | Marks, P. | Hahn, S.

12

Scientific considerations for global drug development

enthalten in: Science translational medicine | 2020

von Wilson, J. | Cheung, K. | Lin, L. | +20

13

Identifying the Risks of Unproven Regenerative Medicine Therapies

enthalten in: JAMA | 2020

von Marks, P. | Hahn, S.

14

Clear Evidence of Safety and Efficacy Is Needed for Stromal Vascular Fraction Products : Commentary on "Arguments for a Different Regulatory Categorization and Framework for Stromal Vascular Fraction"

enthalten in: Stem cells and development | 2020

von Marks, P.

CommentOn: Stem Cells Dev. 2020 Mar 1;29(5):257-262. - PMID 31797749

15

40-O-(2-HYDROXYETHYL)-RAPAMYCIN FOR USE AS A SOLE DRUG SUBSTANCE IN THE TREATMENT OF CARCINOID TUMORS ARISING FROM THE FOREGUT, MIDGUT, OR HINDGUT

enthalten in: Europäisches Patentamt | 2018

von MARKS PETER W | LEBWOHL DAVID

16

Clinical Development Strategies and Considerations for Zika Vaccine Licensure

enthalten in: The Journal of infectious diseases | 2017

von Gruber, M. | Farizo, K. | Pratt, R. | +5

17

Clinical Development Strategies and Considerations for Zika Vaccine Licensure

Erschienen: 2017

von Gruber, M. | Farizo, K. | Pratt, R. | +5

18

The Blood Supply and Men Who Have Sex with Men

enthalten in: The New England journal of medicine | 2017

von Marks, P.

CommentOn: N Engl J Med. 2017 Jan 12;376(2):174-177. - PMID 27959708

19

Decision making in the face of uncertainty : the challenge of emerging infectious diseases

enthalten in: Transfusion | 2017

von Marks, P. | Petersen, L.

20

Clarifying Stem-Cell Therapy's Benefits and Risks

enthalten in: The New England journal of medicine | 2017

von Marks, P. | Witten, C. | Califf, R.